ArticleBMJ open2025
Treatment adherence, social support and coping mechanisms among patients with drug-sensitive tuberculosis: a cross-sectional study in two directly-observed therapy centres in southwest Nigeria.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Measurement of Tuberculosis treatment adherence: A methodological scoping review of observational studies.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate medication adherence, available social support and types of accessible support among patients with drug-sensitive tuberculosis (DS-TB). Coping mechanism(s) in TB management and associations between accessible support(s) and medication adherence were also explored.
designProspective questionnaire-guided cross-sectional study. SETTINGS: The WHO-certified TB directly observed therapy (DOT) clinic of two tertiary hospitals in Ibadan, southwest Nigeria.
participantsAdult patients with DS-TB attending the TB-DOT clinic of the hospitals. OUTCOME MEASURES: Primary outcomes were level of adherence to TB regimens, available social support and type(s) of accessible support. Secondary outcomes were coping mechanisms in TB management, as well as associations between accessible support(s) and medication adherence.
resultsOverall, 152 (89.4%) had optimal adherence. Available social supports were ranked as family (168; 98.8%) >healthcare providers (166; 97.6%) >government (119; 70.0%) >non-governmental organisation (NGO) (118; 69.4%) >religious affiliations (81; 47.6%) >friends (65; 38.2%) >patient association (3; 1.8%). Emotional (168; 98.8%) and financial (137; 80.6%) supports were mostly accessible from family, while drug support (118; 69.4%) was largely received from NGO. Seeking emotional support from family or friends (159; 93.5%) was the most effective coping mechanism. Medication adherence was higher among patients who received health information (p=0.02) and drug support (p=0.03) from the NGO. There was no difference in medication adherence of patients with or without emotional (p=0.20) and financial support (p=0.53) from family, as well as from friends (p=0.31 and p>0.99, respectively).
conclusionNearly ninety per cent of DS-TB patients had optimal adherence. Family was the most available source of social support for TB management, with one hundred and approximately eighty-two per cent respectively citing emotional and financial support as most accessible from the family. Emotional support from family or friends was the most effective coping mechanism in TB management. There is generally a need for initiation and implementation of an expanded social support system for DS-TB patients as a critical step towards achieving the WHO End-TB strategy milestone target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.